BofA analyst Chi Fong lowered the firm’s price target on C4 Therapeutics to $5 from $11 and keeps a Neutral rating on the shares as the firm revisits the setup ahead of competitors’ updates relevant to C4’s lead programs and 2023 company catalysts. BofA lowered its nominal forecast for CFT7455 to about $300M at peak, pending clarity on CFT7455’s competitive profile.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- Tango Therapeutics appoints Crystal as President of Research, Development
- Credit Suisse ups C4 Therapeutics to Neutral on ‘dramatically’ improved outlook
- C4 Therapeutics upgraded to Neutral from Underperform at Credit Suisse
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- C4 Therapeutics downgraded to Underweight from Neutral at JPMorgan
